Evidence map›Paper›PMID 24778270›Full record

ReviewPractical neurology2014

The clinical approach to small fibre neuropathy and painful channelopathy.

Andreas C Themistocleous, Juan D Ramirez, Jordi Serra, David L H Bennett

Open access · hybridAbstract readReview
In one paragraph

Review in Practical neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 2 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 157 citations in OpenAlex.

  1. Pooled it
  2. Small Fiber Neuropathy in Burning Mouth Syndrome: A Systematic Review.International journal of molecular sciences · 2024
    Pooled it
  3. Trial
  4. Trial
  5. A New Simple SCreening Tool for Painful Diabetic Neuropathy (ACT) in Ecuador.Journal of the peripheral nervous system : JPNS · 2026
    Observational
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. A role for pathogenic autoantibodies in small fiber neuropathy?Frontiers in molecular neuroscience · 2023
    Review
  19. Review
  20. Association of electrochemical skin conductance with neuropathy in chemotherapy-treated patients.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Andreas C ThemistocleousNuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, Oxfordshire, UK.
Juan D RamirezNuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, Oxfordshire, UK.
Jordi SerraNeuroscience Technologies, Parc Científic de Barcelona, Barcelona, Spain Department of Neurology, MC Mutual, Barcelona, Spain.
David L H BennettNuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, Oxfordshire, UK.
John Radcliffe Hospital · GBBarcelona Biomedical Research Park · ES

Funding

Wellcome Trust 095698
6 · The paper itself

Abstract

Small fibre neuropathy (SFN) is characterised by structural injury selectively affecting small diameter sensory and/or autonomic axons. The clinical presentation is dominated by pain. SFN complicates a number of common diseases such as diabetes mellitus and is likely to be increasingly encountered. The diagnosis of SFN is demanding as clinical features can be vague and nerve conduction studies normal. New diagnostic techniques, in particular measurement of intraepidermal nerve fibre density, have significantly improved the diagnostic efficiency of SFN. Management is focused on the treatment of the underlying cause and analgesia, as there is no neuroprotective therapy. A recent and significant advance is the finding that a proportion of cases labelled as idiopathic SFN are in fact associated with gain of function mutations of the voltage-gated sodium channels Nav1.7 and Nav1.8 (encoded by the genes SCN9A and SCN10A, respectively). There is a further group of heritable painful conditions in which gain of function mutations in ion channels alter excitability of sensory neurones but do not cause frank axon degeneration; these include mutations in Nav1.7 (causing erythromelalgia and paroxysmal extreme pain disorder) and TRPA1 (resulting in familial episodic pain disorder). These conditions are exceptionally rare but have provided great insight into the nociceptive system as well as yielding potential analgesic drug targets. In patients with no pre-existing risk factor, the investigation of an underlying cause of SFN should be systematic and appropriate for the patient population. In this review, we focus on how to incorporate recent developments in the diagnosis and pathophysiology of SFN into clinical practice.

Indexed as

ChannelopathiesHumansPeripheral Nervous System DiseasesNEUROPATHYPAIN

Identifiers

PMID24778270
PMCPMC4251302
OpenAlexW2076503095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.